Product image of Medaxonum (Ceftriaxone) supplied by GNH India

Medaxonum

Active Ingredient:
Ceftriaxone
Origin:
EU

Medaxonum (Ceftriaxone)

Ceftriaxone, the active ingredient in Medaxonum, is a cephalosporin antibiotic presented as a sterile powder for reconstitution for intramuscular and intravenous use. It provides broad‑spectrum bactericidal activity for serious infections such as pneumonia, meningitis and gonorrhea in adult and pediatric patients.

GNH India supplies Medaxonum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ceftriaxone is a broad‑spectrum cephalosporin used to treat bacterial infections affecting various organ systems.

  • Community‑acquired pneumonia: achieves rapid bacterial clearance and clinical improvement in pulmonary infection.
  • Meningitis: penetrates the cerebrospinal fluid to eradicate the causative pathogens.
  • Gonorrhea: provides effective single‑dose therapy for uncomplicated infection.
  • Urinary tract infections: resolves uropathogenic bacterial growth.
  • Skin and soft‑tissue infections: eliminates common Gram‑positive and Gram‑negative organisms.

How It Works

  • Ceftriaxone binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis, resulting in a bactericidal effect against susceptible organisms.

Side Effects

Ceftriaxone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Injection site pain: discomfort at the site of intramuscular or intravenous administration.
  • Diarrhea: mild to moderate loose stools.
  • Nausea: transient feeling of queasiness.
  • Rash: mild skin erythema.
  • Elevated liver enzymes: transient increase in hepatic transaminases.
  • Transient increase in bilirubin: mild hyperbilirubinemia without clinical significance.

Serious or Rare Side Effects

  • Anaphylaxis: severe, potentially life‑threatening allergic reaction.
  • Stevens‑Johnson syndrome: rare severe mucocutaneous eruption.
  • Clostridioides difficile‑associated diarrhea: severe colitis following disruption of gut flora.
  • Hemolytic anemia: immune‑mediated destruction of red blood cells.
  • Severe hepatic dysfunction: marked liver injury.
  • Renal impairment: acute kidney injury, especially with concomitant nephrotoxins.

Precautions & Warnings

Ceftriaxone requires careful consideration of patient‑specific factors before use.

  • Renal impairment: monitor renal function and adjust dosing as needed.
  • Hepatic dysfunction: observe liver enzyme levels during therapy.
  • Neonates and infants: risk of biliary sludging; use with caution.
  • Allergy to beta‑lactams: avoid in patients with known hypersensitivity.
  • Pregnancy and lactation: prescribe only when benefits outweigh potential risks.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Ceftriaxone can interact with several medicines, influencing safety or efficacy.

Major Interactions (Avoid)

  • Calcium‑containing solutions: may precipitate when mixed intravenously, causing embolism.
  • Warfarin: can potentiate anticoagulant effect, increasing bleeding risk.
  • Aminoglycosides: concurrent use may heighten nephrotoxicity.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may affect renal clearance of ceftriaxone.
  • Probenecid: can increase serum ceftriaxone concentrations, requiring dose adjustment.

Frequently Asked Questions

Medaxonum, containing ceftriaxone, is indicated for serious bacterial infections such as community‑acquired pneumonia, meningitis, gonorrhea, urinary tract infections, and skin or soft‑tissue infections. It is administered by a healthcare professional to achieve rapid bacterial eradication in these conditions.

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing cross‑linking of peptidoglycan strands. This weakens the wall, causing osmotic lysis of susceptible bacteria and resulting in a bactericidal effect.

The specific dose of Medaxonum is determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow local clinical guidelines.

Safety data for ceftriaxone in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as ceftriaxone does pass into breast milk in small amounts.

To place an order, submit an enquiry on the Medaxonum product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Ceftriaxone, the active ingredient in Medaxonum, offers a longer half‑life than many earlier‑generation cephalosporins, allowing once‑daily dosing for many infections. Its broad spectrum covers both Gram‑positive and Gram‑negative organisms, making it a convenient alternative to combination therapy with shorter‑acting agents.

Medaxonum should be stored at 2‑8 °C, protected from light, and must not be frozen. The powder for injection should be reconstituted with the appropriate diluent immediately before administration and used within the time frame recommended in the product label.

Medaxonum is supplied as a sterile powder for injection and is administered by a qualified healthcare professional either intravenously or intramuscularly, according to the prescribed dose and infusion rate. Proper aseptic technique and correct diluent volume are essential for safe administration.

Serious adverse events include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, hemolytic anemia, marked liver injury, and renal impairment. Patients should be monitored closely for signs of hypersensitivity, gastrointestinal disturbance, or changes in liver and kidney function.

Medaxonum is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or any beta‑lactam antibiotics. Caution is also advised for neonates with hyperbilirubinemia, patients with severe renal or hepatic impairment, and those receiving calcium‑containing IV solutions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.